WallStSmart

Regencell Bioscience Holdings Ltd (RGC)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

UTHR leads profitability with a 40.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 57/100 (C).

RGC

Avoid

20

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9

UTHR

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RGC.

UTHRUndervalued (+11.2%)

Margin of Safety

+11.2%

Fair Value

$535.96

Current Price

$564.94

$28.98 discount

UndervaluedFair: $535.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RGC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

UTHR4 strengths · Avg: 9.8/10
Profit MarginProfitability
40.6%10/10

Keeps 41 of every $100 in revenue as profit

Operating MarginProfitability
41.7%10/10

Strong operational efficiency at 41.7%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.3%9/10

Every $100 of equity generates 20 in profit

Areas to Watch

RGC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

UTHR3 concerns · Avg: 2.7/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.6%2/10

Revenue declined 1.6%

EPS GrowthGrowth
-12.2%2/10

Earnings declined 12.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : RGC

The strongest argument for RGC centers on Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.

Bear Case : RGC

The primary concerns for RGC are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

RGC profiles as a value stock while UTHR is a declining play — different risk/reward profiles.

RGC carries more volatility with a beta of 1.87 — expect wider price swings.

RGC is growing revenue faster at 0.0% — sustainability is the question.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

UTHR scores higher overall (57/100 vs 20/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Regencell Bioscience Holdings Ltd

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Regal Entertainment Group, is a film exhibitor in the United States. The company is headquartered in Knoxville, Tennessee.

Visit Website →

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?